COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics
COTA and Guardant Health (Nasdaq: GH) announced a partnership to combine their oncology data resources for advancing precision cancer therapy development. The collaboration merges COTA's research-grade EHR data from academic and community care centers with Guardant's clinicogenomic testing data.
This partnership aims to help researchers better understand correlations between molecular biomarkers, treatments, and clinical outcomes. The combined dataset and AI analytics will support more efficient drug development, particularly given that 97% of cancer clinical trials fail and development can take up to fifteen years.
The collaboration expands COTA's data breadth into solid tumors, focusing on lung, breast, and colorectal cancers. Guardant's data covers all disease stages, from initial tumor profiling to therapy monitoring, while COTA's data tracks complete cancer care journeys.
COTA e Guardant Health (Nasdaq: GH) hanno annunciato una partnership per unire le loro risorse di dati oncologici al fine di avanzare nello sviluppo di terapie oncologiche di precisione. La collaborazione combina i dati di EHR di COTA, di qualità di ricerca, provenienti da centri di assistenza accademici e comunitari con i dati di testing clinico-genomico di Guardant.
Questa partnership ha l'obiettivo di aiutare i ricercatori a comprendere meglio le correlazioni tra biomarcatori molecolari, trattamenti e risultati clinici. Il dataset combinato e le analisi AI supporteranno uno sviluppo dei farmaci più efficiente, considerando che il 97% delle sperimentazioni cliniche sul cancro fallisce e lo sviluppo può richiedere fino a quindici anni.
La collaborazione amplia l'ampiezza dei dati di COTA nei tumori solidi, concentrandosi su cancro ai polmoni, al seno e colorectal. I dati di Guardant coprono tutte le fasi della malattia, dalla profilazione iniziale del tumore al monitoraggio della terapia, mentre i dati di COTA seguono l'intero percorso terapeutico del cancro.
COTA y Guardant Health (Nasdaq: GH) anunciaron una asociación para combinar sus recursos de datos oncológicos con el objetivo de avanzar en el desarrollo de terapias contra el cáncer de precisión. La colaboración une los datos de EHR de COTA de calidad de investigación de centros académicos y de atención comunitaria con los datos de pruebas clínico-genómicas de Guardant.
Este acuerdo tiene como objetivo ayudar a los investigadores a comprender mejor las correlaciones entre biomarcadores moleculares, tratamientos y resultados clínicos. El conjunto de datos combinado y las analíticas de IA apoyarán un desarrollo de fármacos más eficiente, particularmente considerando que el 97% de los ensayos clínicos sobre cáncer fracasa y el desarrollo puede tardar hasta quince años.
La colaboración amplía la amplitud de datos de COTA en tumores sólidos, enfocándose en cáncer de pulmón, mama y colorrectal. Los datos de Guardant cubren todas las etapas de la enfermedad, desde el perfilado inicial del tumor hasta el monitoreo de la terapia, mientras que los datos de COTA rastrean todo el recorrido de atención del cáncer.
COTA와 Guardant Health (Nasdaq: GH)는 정밀 암 치료 개발을 촉진하기 위해 그들의 종양학 데이터 자원을 결합하는 파트너십을 발표했습니다. 이 협력은 학술 및 커뮤니티 치료 센터에서 오는 COTA의 연구 등급 EHR 데이터와 Guardant의 임상 유전체 검사 데이터를 결합합니다.
이 파트너십은 연구자들이 분자 바이오마커, 치료법 및 임상 결과 간의 상관관계를 더 잘 이해하도록 돕는 것을 목표로 합니다. 결합된 데이터 세트와 AI 분석은 더 효율적인 약물 개발을 지원하며, 특히 97%의 암 임상 시험이 실패하고 개발에 최대 15년이 걸릴 수 있다는 점을 고려할 때 그렇습니다.
이 협력은 COTA의 데이터 범위를 고형 종양으로 확장하며, 폐암, 유방암 및 대장암에 초점을 맞춥니다. Guardant의 데이터는 초기 종양 프로파일링에서 치료 모니터링에 이르기까지 모든 질병 단계를 커버하며, COTA의 데이터는 전체 암 치료 경과를 추적합니다.
COTA et Guardant Health (Nasdaq: GH) ont annoncé un partenariat pour combiner leurs ressources de données oncologiques afin de faire avancer le développement de thérapies contre le cancer de précision. La collaboration fusionne les données EHR de COTA, de qualité de recherche, provenant de centres de soins académiques et communautaires avec les données de tests cliniques et génomiques de Guardant.
Ce partenariat vise à aider les chercheurs à mieux comprendre les corrélations entre les biomarqueurs moléculaires, les traitements et les résultats cliniques. L'ensemble de données combiné et les analyses par IA soutiendront un développement de médicaments plus efficace, notamment étant donné que 97 % des essais cliniques sur le cancer échouent et que le développement peut prendre jusqu'à quinze ans.
La collaboration élargit l'étendue des données de COTA dans les tumeurs solides, en se concentrant sur les cancers du poumon, du sein et colorectal. Les données de Guardant couvrent tous les stades de la maladie, du profilage tumoral initial à la surveillance thérapeutique, tandis que les données de COTA retracent l'ensemble du parcours de soins du cancer.
COTA und Guardant Health (Nasdaq: GH) gaben eine Partnerschaft bekannt, um ihre onkologischen Datenressourcen zu kombinieren und die Entwicklung präziser Krebstherapien voranzutreiben. Die Zusammenarbeit vereint die forschungsbasierten EHR-Daten von COTA aus akademischen und kommunalen Versorgungszentren mit den klinischen Genomtests von Guardant.
Das Ziel dieser Partnerschaft ist es, Forschern zu helfen, die Zusammenhänge zwischen molekularen Biomarkern, Behandlungen und klinischen Ergebnissen besser zu verstehen. Der kombinierte Datensatz und die KI-Analysen werden eine effizientere Arzneimittelentwicklung unterstützen, insbesondere angesichts der Tatsache, dass 97% der klinischen Studien zu Krebs scheitern und die Entwicklung bis zu fünfzehn Jahre dauern kann.
Die Zusammenarbeit erweitert die Datenbasis von COTA auf solide Tumoren mit Fokus auf Lungen-, Brust- und Kolorektalkrebs. Die Daten von Guardant decken alle Krankheitsstadien ab, von der initialen Tumorprofilierung bis zur Therapieüberwachung, während die Daten von COTA den gesamten Verlauf der Krebsbehandlung verfolgen.
- Partnership combines comprehensive datasets to accelerate cancer drug development
- Expansion into solid tumors (lung, breast, and colorectal cancers) broadens market reach
- Integration of longitudinal serial testing data enhances research capabilities
- None.
Insights
This strategic partnership marks a significant advancement in precision oncology by combining COTA's research-grade EHR data with Guardant Health's clinicogenomic testing capabilities. The collaboration addresses a critical industry challenge - the
The partnership's value proposition centers on three key elements: longitudinal serial testing data, enhanced biomarker validation and accelerated drug development timelines. By integrating detailed tumor biology information with patient outcomes across diverse populations, particularly in lung, breast and colorectal cancers, researchers can better predict treatment responses and identify targeted therapies more efficiently.
Think of this as creating a 'GPS for cancer treatment' - instead of testing multiple routes blindly, researchers can now navigate drug development with precise, data-driven insights, potentially reducing the typical 15-year development timeline and associated costs.
For Guardant Health's market position, this partnership strengthens their competitive moat in the precision oncology space. The deal expands their data ecosystem beyond genetic testing into comprehensive clinical outcomes, creating a powerful feedback loop that enhances their core product offerings and market value proposition.
The collaboration's focus on solid tumors - particularly lung, breast and colorectal cancers - targets high-value market segments with significant commercial potential. This positions Guardant to capture greater market share in the rapidly growing precision medicine market, estimated at
From an investor perspective, this partnership demonstrates Guardant's strategic execution in building sustainable competitive advantages through data assets, which could translate into stronger pricing power and expanded market opportunities in the biopharmaceutical services segment.
Using the extensive dataset and AI analytics the collaboration provides, research scientists can more easily understand and further validate correlations between molecular biomarkers, treatment decisions and clinical outcomes. They can also gain greater insights into existing data research and gather the comprehensive data—including critical longitudinal serial testing information—needed to optimize drug development and accelerate programs that treat cancer across diverse patient populations.
“Clinicogenomic data empowers research scientists to test hypotheses by studying patient genomic profiles and real-world outcomes to guide the development of targeted therapies that can be used to personalize treatment for each cancer patient,” said Dr. C.K. Wang, chief medical officer at COTA. “Connecting Guardant’s data to COTA’s in-depth, real-world oncology data assets will also allow researchers to anticipate treatment responses and accelerate drug development for existing and new population segments.”
The drug development process can take up to fifteen years, with
“The real-world data partnership with COTA marks another milestone in our mission to conquer cancer with data,” said Craig Eagle, MD, Guardant Health chief medical officer. “Giving biopharmaceutical researchers the ability to connect detailed information about tumor biology and therapy response with real-world patient outcome data will expedite the discovery of new biomarker-based therapies for patients and make the drug development process more economical as well.”
Guardant’s extensive real-world longitudinal serial testing datasets span all stages of the disease, from initial tumor profiling for therapy selection to recurrence and therapy response monitoring, while COTA’s highly curated data tracks a patient’s complete cancer care journey, drawing from both academic and community care center settings. This new collaboration with Guardant deepens COTA’s data by expanding its breadth into solid tumors, particularly lung, breast, and colorectal cancers, creating a broader, more diverse data set with considerable patient overlap for enhanced clinical insights.
About COTA, Inc.
Founded by oncologists, COTA is committed to creating a precise, patient-first approach to cancer care using real-world data. The company leverages technology-supported data abstraction methods to make sense of complex, fragmented patient data from the real world. Offering the highest quality oncology real-world data from leading academic and community-based cancer centers and an advanced analytics platform, COTA partners with leading life sciences companies, providers, and payers to ensure that everyone touched by cancer has a clear path to the right care. To learn more about COTA and how to fast-track improvements in cancer care and treatment with comprehensive and diverse real-world data and analytics, visit cotahealthcare.com.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241219536913/en/
Press Contacts
For COTA
Jared Rosen
jared@12080group.com
For Guardant Health
Mike Weist
mweist@guardanthealth.com
Source: COTA Inc.
FAQ
What is the purpose of COTA and Guardant Health's (GH) new partnership?
Which cancer types will the COTA-GH partnership focus on?
How will the GH partnership improve cancer drug development?
What types of data will be combined in the COTA-GH collaboration?
